HIV-1 Latency in Monocytes/macrophages

Overview

Journal Viruses

Publisher MDPI

Specialty Microbiology

Date 2014 Apr 25

PMID 24759213

Citations 119

Authors

Amit Kumar

Wasim Abbas

Georges Herbein

Affiliations

Soon will be listed here.

Abstract

Human immunodeficiency virus type 1 (HIV-1) targets CD4+ T cells and cells of the monocyte/macrophage lineage. HIV pathogenesis is characterized by the depletion of T lymphocytes and by the presence of a population of cells in which latency has been established called the HIV-1 reservoir. Highly active antiretroviral therapy (HAART) has significantly improved the life of HIV-1 infected patients. However, complete eradication of HIV-1 from infected individuals is not possible without targeting latent sources of infection. HIV-1 establishes latent infection in resting CD4+ T cells and findings indicate that latency can also be established in the cells of monocyte/macrophage lineage. Monocyte/macrophage lineage includes among others, monocytes, macrophages and brain resident macrophages. These cells are relatively more resistant to apoptosis induced by HIV-1, thus are important stable hideouts of the virus. Much effort has been made in the direction of eliminating HIV-1 resting CD4+ T-cell reservoirs. However, it is impossible to achieve a cure for HIV-1 without considering these neglected latent reservoirs, the cells of monocyte/macrophage lineage. In this review we will describe our current understanding of the mechanism of latency in monocyte/macrophage lineage and how such cells can be specifically eliminated from the infected host.

Citing Articles

Effect of Kinases in Extracellular Vesicles from HIV-1-Infected Cells on Bystander Cells.

Mensah G, Williams A, Khatkar P, Kim Y, Erickson J, Duverger A Cells. 2025; 14(2.

PMID: 39851547 PMC: 11763833. DOI: 10.3390/cells14020119.

Interaction of chikungunya virus glycoproteins with macrophage factors controls virion production.

Yao Z, Ramachandran S, Huang S, Kim E, Jami-Alahmadi Y, Kaushal P EMBO J. 2024; 43(20):4625-4655.

PMID: 39261662 PMC: 11480453. DOI: 10.1038/s44318-024-00193-3.

Cognitive Impairment in People Living with HIV and the Impact of Mood: Results from a Cross-Sectional Study.

Salis F, Belfiori M, Bellisai A, Bernardini E, Murtas M, Piras R J Clin Med. 2024; 13(6).

PMID: 38541857 PMC: 10971399. DOI: 10.3390/jcm13061631.

Gesicles packaging dCas9-VPR ribonucleoprotein complexes can combine with vorinostat and promote HIV proviral transcription.

Fisher M, Chaudhry W, Campbell L Mol Ther Methods Clin Dev. 2024; 32(1):101203.

PMID: 38390557 PMC: 10881426. DOI: 10.1016/j.omtm.2024.101203.

Functional Analysis of KAP1/TRIM28 Requirements for HIV-1 Transcription Activation.

Randolph K, Hyder U, Challa A, Perez E, DOrso I Viruses. 2024; 16(1).

PMID: 38257816 PMC: 10819576. DOI: 10.3390/v16010116.

References

Christ F, Debyser Z . The LEDGF/p75 integrase interaction, a novel target for anti-HIV therapy. Virology. 2012; 435(1):102-9. DOI: 10.1016/j.virol.2012.09.033. View

Coull J, Romerio F, Sun J, Volker J, Galvin K, Davie J . The human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via recruitment of histone deacetylase 1. J Virol. 2000; 74(15):6790-9. PMC: 112196. DOI: 10.1128/jvi.74.15.6790-6799.2000. View

Bukrinsky M, Sharova N, Dempsey M, Stanwick T, Bukrinskaya A, Haggerty S . Active nuclear import of human immunodeficiency virus type 1 preintegration complexes. Proc Natl Acad Sci U S A. 1992; 89(14):6580-4. PMC: 49545. DOI: 10.1073/pnas.89.14.6580. View

Cherrier T, Douce V, Eilebrecht S, Riclet R, Marban C, Dequiedt F . CTIP2 is a negative regulator of P-TEFb. Proc Natl Acad Sci U S A. 2013; 110(31):12655-60. PMC: 3732990. DOI: 10.1073/pnas.1220136110. View

Fernandez Larrosa P, Croci D, Riva D, Bibini M, Luzzi R, Saracco M . Apoptosis resistance in HIV-1 persistently-infected cells is independent of active viral replication and involves modulation of the apoptotic mitochondrial pathway. Retrovirology. 2008; 5:19. PMC: 2276517. DOI: 10.1186/1742-4690-5-19. View

Varatharajan L, Thomas S . The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research. Antiviral Res. 2009; 82(2):A99-109. PMC: 2678986. DOI: 10.1016/j.antiviral.2008.12.013. View

Taube R, Peterlin M . Lost in transcription: molecular mechanisms that control HIV latency. Viruses. 2013; 5(3):902-27. PMC: 3705304. DOI: 10.3390/v5030902. View

Wang X, Ye L, Hou W, Zhou Y, Wang Y, Metzger D . Cellular microRNA expression correlates with susceptibility of monocytes/macrophages to HIV-1 infection. Blood. 2008; 113(3):671-4. PMC: 2628373. DOI: 10.1182/blood-2008-09-175000. View

Chun T, Engel D, Berrey M, Shea T, Corey L, Fauci A . Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Natl Acad Sci U S A. 1998; 95(15):8869-73. PMC: 21169. DOI: 10.1073/pnas.95.15.8869. View

10.

He G, Margolis D . Counterregulation of chromatin deacetylation and histone deacetylase occupancy at the integrated promoter of human immunodeficiency virus type 1 (HIV-1) by the HIV-1 repressor YY1 and HIV-1 activator Tat. Mol Cell Biol. 2002; 22(9):2965-73. PMC: 133763. DOI: 10.1128/MCB.22.9.2965-2973.2002. View

11.

Triboulet R, Mari B, Lin Y, Chable-Bessia C, Bennasser Y, Lebrigand K . Suppression of microRNA-silencing pathway by HIV-1 during virus replication. Science. 2007; 315(5818):1579-82. DOI: 10.1126/science.1136319. View

12.

Miyagi E, Schwartzkopff F, Plishka R, Buckler-White A, Clouse K, Strebel K . APOBEC3G-independent reduction in virion infectivity during long-term HIV-1 replication in terminally differentiated macrophages. Virology. 2008; 379(2):266-74. PMC: 2614695. DOI: 10.1016/j.virol.2008.06.033. View

13.

Easley R, Van Duyne R, Coley W, Guendel I, Dadgar S, Kehn-Hall K . Chromatin dynamics associated with HIV-1 Tat-activated transcription. Biochim Biophys Acta. 2009; 1799(3-4):275-85. PMC: 2838975. DOI: 10.1016/j.bbagrm.2009.08.008. View

14.

Stewart M, Li J, Wong J . Relationship between histone H3 lysine 9 methylation, transcription repression, and heterochromatin protein 1 recruitment. Mol Cell Biol. 2005; 25(7):2525-38. PMC: 1061631. DOI: 10.1128/MCB.25.7.2525-2538.2005. View

15.

Koppensteiner H, Brack-Werner R, Schindler M . Macrophages and their relevance in Human Immunodeficiency Virus Type I infection. Retrovirology. 2012; 9:82. PMC: 3484033. DOI: 10.1186/1742-4690-9-82. View

16.

Marban C, Suzanne S, Dequiedt F, de Walque S, Redel L, Van Lint C . Recruitment of chromatin-modifying enzymes by CTIP2 promotes HIV-1 transcriptional silencing. EMBO J. 2007; 26(2):412-23. PMC: 1783449. DOI: 10.1038/sj.emboj.7601516. View

17.

Herbein G, Gras G, Khan K, Abbas W . Macrophage signaling in HIV-1 infection. Retrovirology. 2010; 7:34. PMC: 2865443. DOI: 10.1186/1742-4690-7-34. View

18.

Sheehy A, Gaddis N, Choi J, Malim M . Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature. 2002; 418(6898):646-50. DOI: 10.1038/nature00939. View

19.

Berre S, Gaudin R, de Alencar B, Desdouits M, Chabaud M, Naffakh N . CD36-specific antibodies block release of HIV-1 from infected primary macrophages and its transmission to T cells. J Exp Med. 2013; 210(12):2523-38. PMC: 3832921. DOI: 10.1084/jem.20130566. View

20.

Hammer S, Squires K, Hughes M, Grimes J, Demeter L, Currier J . A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med. 1997; 337(11):725-33. DOI: 10.1056/NEJM199709113371101. View